Brii Biosciences Limited (BRIBF)
OTCMKTS
· Delayed Price · Currency is USD
0.126
0.00 (0.00%)
At close: Jul 8, 2024
Brii Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Operating Revenue | - | 0.62 | 51.63 | - | - | - |
| Other Revenue | 38.38 | 55.71 | 70.65 | 92.54 | 82.22 | 20.2 |
| Revenue | 38.38 | 56.32 | 122.28 | 92.54 | 82.22 | 20.2 |
| Revenue Growth (YoY) | -71.46% | -53.94% | 32.13% | 12.56% | 307.10% | - |
| Gross Profit | 38.38 | 56.32 | 122.28 | 92.54 | 82.22 | 20.2 |
| Selling, General & Admin | 172.34 | 197.92 | 195.49 | 208.4 | 103.4 | 63.33 |
| Research & Development | 326.7 | 402.71 | 440.63 | 494.62 | 875.8 | 83.79 |
| Operating Expenses | 532 | 600.62 | 636.12 | 703.02 | 979.19 | 147.12 |
| Operating Income | -493.62 | -544.3 | -513.85 | -610.48 | -896.97 | -126.92 |
| Interest Expense | -1.23 | -0.49 | -0.85 | -1.18 | -1.67 | -1.11 |
| Interest & Investment Income | 110.36 | 108.02 | 37.2 | 6.49 | 2.41 | 0.14 |
| Currency Exchange Gain (Loss) | 137.34 | 121.59 | -43.98 | 0.27 | -6.97 | 3.14 |
| Other Non Operating Income (Expenses) | - | - | - | - | - | -401.58 |
| EBT Excluding Unusual Items | -247.15 | -315.18 | -521.47 | -604.9 | -903.21 | -526.33 |
| Gain (Loss) on Sale of Investments | -23.64 | 136.24 | 31.69 | 44.8 | -15.02 | 5.3 |
| Asset Writedown | - | -5.43 | - | - | - | - |
| Other Unusual Items | - | - | - | -3,631 | -365.28 | - |
| Pretax Income | -270.78 | -184.37 | -489.78 | -4,191 | -1,284 | -521.03 |
| Earnings From Continuing Operations | -270.78 | -184.37 | -489.78 | -4,191 | -1,284 | -521.03 |
| Minority Interest in Earnings | 5.34 | 9.54 | 5.47 | 27.24 | 93.91 | - |
| Net Income | -265.45 | -174.83 | -484.31 | -4,164 | -1,190 | -521.03 |
| Net Income to Common | -265.45 | -174.83 | -484.31 | -4,164 | -1,190 | -521.03 |
| Shares Outstanding (Basic) | 729 | 728 | 723 | 439 | 191 | 179 |
| Shares Outstanding (Diluted) | 729 | 728 | 723 | 439 | 191 | 179 |
| Shares Change (YoY) | 0.40% | 0.64% | 64.78% | 129.57% | 7.08% | - |
| EPS (Basic) | -0.36 | -0.24 | -0.67 | -9.48 | -6.22 | -2.92 |
| EPS (Diluted) | -0.36 | -0.24 | -0.67 | -9.48 | -6.22 | -2.92 |
| Free Cash Flow | -466.81 | -594.01 | -496.28 | -880.49 | -403.72 | -91.42 |
| Free Cash Flow Per Share | -0.64 | -0.82 | -0.69 | -2.01 | -2.11 | -0.51 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -1286.14% | -966.41% | -420.22% | -659.68% | -1090.97% | -628.46% |
| Profit Margin | -691.63% | -310.41% | -396.07% | -4499.42% | -1446.89% | -2579.86% |
| Free Cash Flow Margin | -1216.27% | -1054.67% | -405.86% | -951.44% | -491.03% | -452.68% |
| EBITDA | -488.48 | -537.31 | -505.5 | -602.8 | -890.79 | -124.11 |
| D&A For EBITDA | 5.14 | 6.99 | 8.35 | 7.68 | 6.19 | 2.81 |
| EBIT | -493.62 | -544.3 | -513.85 | -610.48 | -896.97 | -126.92 |
Source: S&P Capital IQ. Standard template. Financial Sources.